alexa
Reach Us +44-1647-403003
Incomplete Success of Angioinhibitor Therapy in Cancer: Estimation of Contribution of Pro-angiogenic Activity of Patient Thyroid Hormone | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Incomplete Success of Angioinhibitor Therapy in Cancer: Estimation of Contribution of Pro-angiogenic Activity of Patient Thyroid Hormone

Paul J Davis1,2*, Murat Yalcin1, Hung-Yun Lin3, Heng-Yuan Tang1, Aleck Hercbergs4, John T. Leith5, Faith B Davis1, Mary K Luidens2, Shaker A Mousa1

1Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA

2Department of Medicine, Albany Medical College, Albany, NY, USA

3Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

4Department of Radiation Oncology, the Cleveland Clinic, Cleveland, OH, USA

5Rhode Island Nuclear Research Center, Providence, RI, USA

*Corresponding Author:
Paul J Davis, M.D.
Pharmaceutical Research Institute
Albany College of Pharmacy and Health Sciences
One Discovery Drive, Rensselaer, NY 12144, USA
Tel: 518 428 7848
Fax: 518 694 7567
E-mail: [email protected]

Received Date: November 01, 2013; Accepted Date: December 26, 2013; Published Date: December 30, 2013

Citation: Davis PJ, Yalcin M, Lin HY, Tang HY, Hercbergs A, et al. (2013) Incomplete Success of Angioinhibitor Therapy in Cancer: Estimation of Contribution of Proangiogenic Activity of Patient Thyroid Hormone. J Cancer Sci Ther 5:441-445. doi: 10.4172/1948-5956.1000238

Copyright: © 2013 Davis PJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Despite the obvious promise of the strategy, pharmaceutical angioinhibition has had variable success in clinical cancer management. Thyroid hormone is a potent pro-angiogenic factor. Endogenous circulating levels of proangiogenic thyroid hormone in cancer patients treated with anti-angiogenic drugs may contribute to host resistance to angioinhibition and explain, at least in part, the variable cancer chemotherapeutic responses obtained with anti-angiogenic agents. The chick chorioallantoic membrane (CAM) angiogenesis assay accepts human tumor xenografts and is a system in which individual patient blood samples can be tested in xenograft vasculature for anti-angiogenic content—including thyroid hormone—in the presence of angioinhibitory drug dose escalation. The assay may also be used to screen individual patient tumor biopsy xenografts for susceptibility to angioinhibition.

Keywords

Top